Advertisement
News
Advertisement

Perrigo Announces Conclusion of the FDA Re-Inspection

Tue, 04/12/2011 - 9:35am
Bio-Medicine.Org

ALLEGAN, Mich., April 12, 2011 /PRNewswire/ -- Perrigo (Nasdaq: PRGO; TASE) today announced that the Detroit Office of the Food and Drug Administration (FDA) has concluded its re-inspection of Perrigo's Allegan facility. The FDA has informed Perrigo that, effective immediately, the Company has an acceptable regulatory status, such that any pending export license and ANDA applications from this facility will once again be eligible for review and approval.

Perrigo's Chairman and CEO Joseph C. Papa stated, "On behalf of Perrigo, I want to thank the FDA Detroit District for making the re-inspection of our facilities a priority and for working cooperatively with us to resolve the issues previously raised in the Warning Letter. We are convinced that this process has made us a better company by enhancing the quality of our affordable healthcare products for our customers."  

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, active pharmaceutical ingredients (API) and pharmaceutical and medical diagnostic products. The Company is the world's largest store brand manufacturer of OTC pharmaceutical products and infant formulas. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Israel, Mexico, the United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and ot

'/>"/>

SOURCE

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading